Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2
Summary: Different immune-mediated diseases have been described after SARS-CoV-2 vaccination, with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) being one of the possible side effects. In this study, a total of 35 patients presented ANCA for the first time during 2021, wit...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-08-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004222011191 |
| _version_ | 1798042781995761664 |
|---|---|
| author | Juan Irure-Ventura Lara Belmar-Vega Gema Fernández-Fresnedo Elena González-López Carolina Castro-Hernández Emilio Rodrigo-Calabia Milagros Heras-Vicario Juan Carlos Ruiz San Millán Marcos López-Hoyos |
| author_facet | Juan Irure-Ventura Lara Belmar-Vega Gema Fernández-Fresnedo Elena González-López Carolina Castro-Hernández Emilio Rodrigo-Calabia Milagros Heras-Vicario Juan Carlos Ruiz San Millán Marcos López-Hoyos |
| author_sort | Juan Irure-Ventura |
| collection | DOAJ |
| description | Summary: Different immune-mediated diseases have been described after SARS-CoV-2 vaccination, with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) being one of the possible side effects. In this study, a total of 35 patients presented ANCA for the first time during 2021, with the number during 2019 being 15. Twenty-seven out of thirty-five patients developed ANCA after vaccination. Two of them developed these antibodies after receiving the first dose (7.4%), and 25 patients developed ANCA after the second dose of the vaccine (92.6%), with BNT162b2 being the main vaccine received by these patients. In 97.1% of the patients who developed ANCA during 2021, the positivity of ANCA was accompanied by systemic involvement, with renal and respiratory tracts being the main organs affected. Therefore, an increase in the development of AAV has been observed during 2021 in comparison with 2019, which could be due to the administration of SARS-CoV-2 vaccine. |
| first_indexed | 2024-04-11T22:40:22Z |
| format | Article |
| id | doaj.art-3136b8cf6a6547fc811cee5440ad984b |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-04-11T22:40:22Z |
| publishDate | 2022-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-3136b8cf6a6547fc811cee5440ad984b2022-12-22T03:59:00ZengElsevieriScience2589-00422022-08-01258104847Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2Juan Irure-Ventura0Lara Belmar-Vega1Gema Fernández-Fresnedo2Elena González-López3Carolina Castro-Hernández4Emilio Rodrigo-Calabia5Milagros Heras-Vicario6Juan Carlos Ruiz San Millán7Marcos López-Hoyos8Immunology Service, University Hospital Marqués de Valdecilla, 39008 Santander, Spain; Transplantation and Autoimmunity Laboratory, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, SpainTransplantation and Autoimmunity Laboratory, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, Spain; Nephrology Service, University Hospital Marqués de Valdecilla, 39008 Santander, SpainTransplantation and Autoimmunity Laboratory, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, Spain; Nephrology Service, University Hospital Marqués de Valdecilla, 39008 Santander, SpainImmunology Service, University Hospital Marqués de Valdecilla, 39008 Santander, Spain; Transplantation and Autoimmunity Laboratory, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, SpainImmunology Service, University Hospital Marqués de Valdecilla, 39008 Santander, Spain; Transplantation and Autoimmunity Laboratory, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, SpainTransplantation and Autoimmunity Laboratory, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, Spain; Nephrology Service, University Hospital Marqués de Valdecilla, 39008 Santander, SpainTransplantation and Autoimmunity Laboratory, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, Spain; Nephrology Service, University Hospital Marqués de Valdecilla, 39008 Santander, SpainTransplantation and Autoimmunity Laboratory, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, Spain; Nephrology Service, University Hospital Marqués de Valdecilla, 39008 Santander, SpainImmunology Service, University Hospital Marqués de Valdecilla, 39008 Santander, Spain; Transplantation and Autoimmunity Laboratory, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, Spain; Faculty of Medicine, University of Cantabria, 39011 Santander, Spain; Corresponding authorSummary: Different immune-mediated diseases have been described after SARS-CoV-2 vaccination, with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) being one of the possible side effects. In this study, a total of 35 patients presented ANCA for the first time during 2021, with the number during 2019 being 15. Twenty-seven out of thirty-five patients developed ANCA after vaccination. Two of them developed these antibodies after receiving the first dose (7.4%), and 25 patients developed ANCA after the second dose of the vaccine (92.6%), with BNT162b2 being the main vaccine received by these patients. In 97.1% of the patients who developed ANCA during 2021, the positivity of ANCA was accompanied by systemic involvement, with renal and respiratory tracts being the main organs affected. Therefore, an increase in the development of AAV has been observed during 2021 in comparison with 2019, which could be due to the administration of SARS-CoV-2 vaccine.http://www.sciencedirect.com/science/article/pii/S2589004222011191Health sciencesClinical findingDisease |
| spellingShingle | Juan Irure-Ventura Lara Belmar-Vega Gema Fernández-Fresnedo Elena González-López Carolina Castro-Hernández Emilio Rodrigo-Calabia Milagros Heras-Vicario Juan Carlos Ruiz San Millán Marcos López-Hoyos Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2 iScience Health sciences Clinical finding Disease |
| title | Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2 |
| title_full | Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2 |
| title_fullStr | Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2 |
| title_full_unstemmed | Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2 |
| title_short | Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2 |
| title_sort | increased induction of de novo serum anca and anca associated vasculitis after mass vaccination against sars cov 2 |
| topic | Health sciences Clinical finding Disease |
| url | http://www.sciencedirect.com/science/article/pii/S2589004222011191 |
| work_keys_str_mv | AT juanirureventura increasedinductionofdenovoserumancaandancaassociatedvasculitisaftermassvaccinationagainstsarscov2 AT larabelmarvega increasedinductionofdenovoserumancaandancaassociatedvasculitisaftermassvaccinationagainstsarscov2 AT gemafernandezfresnedo increasedinductionofdenovoserumancaandancaassociatedvasculitisaftermassvaccinationagainstsarscov2 AT elenagonzalezlopez increasedinductionofdenovoserumancaandancaassociatedvasculitisaftermassvaccinationagainstsarscov2 AT carolinacastrohernandez increasedinductionofdenovoserumancaandancaassociatedvasculitisaftermassvaccinationagainstsarscov2 AT emiliorodrigocalabia increasedinductionofdenovoserumancaandancaassociatedvasculitisaftermassvaccinationagainstsarscov2 AT milagrosherasvicario increasedinductionofdenovoserumancaandancaassociatedvasculitisaftermassvaccinationagainstsarscov2 AT juancarlosruizsanmillan increasedinductionofdenovoserumancaandancaassociatedvasculitisaftermassvaccinationagainstsarscov2 AT marcoslopezhoyos increasedinductionofdenovoserumancaandancaassociatedvasculitisaftermassvaccinationagainstsarscov2 |